Targeting Lactylation to Overcome Cancer Therapy Resistance

Text
A breakthrough in cancer research suggests that targeting lactylation—a metabolic process involving the addition of lactate to proteins—could address a critical challenge in therapy resistance, according to a report from News-Medical. The finding, published on August 6, 2026, highlights a potential pathway to improve the efficacy of existing treatments like chemotherapy and immunotherapy, which often fail as tumors develop resistance.

Lactylation, first identified in 2019, is a post-translational modification that alters the function of proteins involved in gene expression and cellular metabolism. Researchers at the University of California, San Francisco (UCSF), whose work was cited in the report, found that abnormal lactylation levels in cancer cells correlate with reduced sensitivity to radiation and chemotherapy. By inhibiting enzymes responsible for lactylation, such as histone lactyltransferases, the team observed increased tumor cell death in preclinical models.

Text
The study, led by Dr. Mei Lin, a molecular biologist at UCSF, focused on how lactylation affects the tumor microenvironment. "Cancer cells reprogram their metabolism to survive harsh conditions, including those induced by therapy," Lin explained. "Lactylation appears to be a key driver of this adaptation, allowing tumors to evade treatment and proliferate." The research, published in Nature Cancer, involved analyzing over 500 tumor samples across multiple cancer types, including lung, breast, and colorectal cancers.

Text
Current cancer therapies often target rapidly dividing cells, but resistant tumors exploit metabolic flexibility to persist. For example, chemotherapy-induced stress can trigger lactylation, which in turn stabilizes proteins that promote DNA repair and cell survival. This mechanism may explain why some patients experience initial responses to treatment but later develop resistance.

Text
The implications of this discovery are significant. By disrupting lactylation, scientists could potentially "re-sensitize" tumors to existing therapies. In laboratory experiments, inhibitors of lactylation-related enzymes enhanced the effectiveness of radiation therapy in mouse models of pancreatic cancer. These results, while preliminary, suggest a new approach to combination treatments.

Text
However, challenges remain. Lactylation is not unique to cancer cells; it also occurs in healthy tissues, raising concerns about off-target effects. Additionally, the long-term safety and efficacy of lactylation inhibitors have not been tested in human trials. "We need to ensure that these drugs do not interfere with normal cellular functions," said Dr. James Carter, an oncologist at the Mayo Clinic, who was not involved in the study.

Text
The research also underscores the growing emphasis on metabolism in cancer treatment. Over the past decade, scientists have increasingly recognized the role of metabolic reprogramming in tumor survival. Targeting metabolic pathways, including lactylation, represents a shift from traditional approaches that focus solely on genetic mutations.

Text
News-Medical cited a 2025 review in The Lancet Oncology that noted the "urgent need for therapies that address metabolic resilience in cancer." The review highlighted lactylation as a promising target, given its role in regulating both epigenetic and metabolic processes.

Text
While the findings are encouraging, experts caution against premature optimism. "This is a critical step forward, but we are still years away from clinical applications," said Dr. Aisha Patel, a cancer biologist at Harvard Medical School. "More research is needed to understand the full scope of lactylation’s role and to develop safe, effective interventions."

Text
The study has already spurred interest from pharmaceutical companies. Two biotech firms, MetabRx and OncoMet, have announced plans to develop small-molecule inhibitors of lactylation enzymes. Their efforts will likely face regulatory hurdles, as the U.S. Food and Drug Administration (FDA) requires extensive safety data before approving new cancer therapies.

Text
For patients, the discovery offers a glimpse of future possibilities. "If we can target these metabolic vulnerabilities, we may be able to extend survival and improve quality of life for those with resistant cancers," said Dr. Lin. "This is just the beginning of a new era in cancer treatment."

Text
As research progresses, the focus will remain on translating laboratory findings into real-world solutions. The next steps include identifying biomarkers to predict which patients would benefit most from lactylation-targeted therapies and refining drug candidates to minimize side effects.

Text
The study’s authors emphasized that collaboration between academia, industry, and regulatory agencies will be essential. "This is a complex problem that requires a multidisciplinary approach," Lin said. "We are optimistic, but we must proceed with caution to ensure patient safety and treatment efficacy."